Formulary Overlay

BEXSERO (Meningococcal Group B Vaccine) targets 4 distinct antigenic components to help protect against meningitis B strains1,2

BEXSERO induces antibodies to these 4 antigenic components3,*

Antigenic Component: fHbp

Contributes to bacterial survival in the blood4,5

Antigenic Component: NadA

Promotes adherence of bacteria to human epithelial cells and invasion into these cells6-8

Antigenic Component: PorA

Major Outer Membrane Vesicle protein has been shown to induce strain-specific bactericidal response9

Antigenic Component: NHBA

Contributes to bacterial survival in the blood10

*

The susceptibility of serogroup B meningococci to complement-mediated antibody-dependent killing following vaccination with BEXSERO is dependent on both the antigenic similarity of the bacterial and vaccine antigens, as well as the amount of antigen expressed on the surface of the invading meningococci.3

fHbp=factor H binding protein; NadA=Neisserial adhesin A; NHBA=Neisserial Heparin Binding Antigen; PorA=Porin A P1.4 present in Outer Membrane Vesicles (OMV).

REFERENCES:

  • Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11(7):969-985. doi:10.1517/14712598.2011.585965
  • Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Fiol Rev. 2010;74(1):81-94.
  • Prescribing Information for BEXSERO.
  • Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501-510. doi:10.4049/jimmunol.177.1.501
  • Schneider MC, Prosser BE, Caesar JJE, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458(7240):890-893. doi:10.1038/nature07769
  • Capecchi B, Adu-Bobie J, DiMarcello F, et al. Neisseria meningitidis NadA is a new invasion which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55(3):687-698.
  • Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195(11):1445-1454.
  • Mazzon C, Baldani-Guerra B, Cecchini P, et al. IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol. 2007;179(6):3904-3916. doi:10.4049/jimmunol.179.6.3904
  • Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2.4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486-491.
  • Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107(8):3770-3775. doi:10.1073/pnas.0915162107